scholarly journals Predicting risk of sudden cardiac death in patients with cardiac sarcoidosis using multimodality imaging and personalized heart modeling in a multivariable classifier

2021 ◽  
Vol 7 (31) ◽  
pp. eabi8020
Author(s):  
Julie K. Shade ◽  
Adityo Prakosa ◽  
Dan M. Popescu ◽  
Rebecca Yu ◽  
David R. Okada ◽  
...  

Cardiac sarcoidosis (CS), an inflammatory disease characterized by formation of granulomas in the heart, is associated with high risk of sudden cardiac death (SCD) from ventricular arrhythmias. Current “one-size-fits-all” guidelines for SCD risk assessment in CS result in insufficient appropriate primary prevention. Here, we present a two-step precision risk prediction technology for patients with CS. First, a patient’s arrhythmogenic propensity arising from heterogeneous CS-induced ventricular remodeling is assessed using a novel personalized magnetic-resonance imaging and positron-emission tomography fusion mechanistic model. The resulting simulations of arrhythmogenesis are fed, together with a set of imaging and clinical biomarkers, into a supervised classifier. In a retrospective study of 45 patients, the technology achieved testing results of 60% sensitivity [95% confidence interval (CI): 57-63%], 72% specificity [95% CI: 70-74%], and 0.754 area under the receiver operating characteristic curve [95% CI: 0.710-0.797]. It outperformed clinical metrics, highlighting its potential to transform CS risk stratification.

2009 ◽  
Vol 183 (1-3) ◽  
pp. e1-e5 ◽  
Author(s):  
Irene Riezzo ◽  
Francesco Ventura ◽  
Stefano D’Errico ◽  
Margherita Neri ◽  
Emanuela Turillazzi ◽  
...  

2014 ◽  
Vol 37 (8) ◽  
pp. 493-498 ◽  
Author(s):  
Pieter A. Vriesendorp ◽  
Arend F.L. Schinkel ◽  
Natasja M. S. de Groot ◽  
Ron T. van Domburg ◽  
Folkert J. ten Cate ◽  
...  

2015 ◽  
Vol 16 ◽  
pp. S1-S3
Author(s):  
Yingming Amy Chen ◽  
Djeven Deva ◽  
Anish Kirpalani ◽  
Vikram Prabhudesai ◽  
Danny W. Marcuzzi ◽  
...  

2020 ◽  
Vol 13 (2) ◽  
pp. e232047
Author(s):  
Deepti Bhandare ◽  
Anupama Kottam

Cardiac sarcoidosis (CS) is challenging to determine, consequently is under-recognised in clinical practice. The accurate prevalence of CS is possibly underestimated due to unspecific symptoms, subclinical illness and the dearth of universally accepted diagnostic criteria. Totally, non-invasive diagnosis of CS was proposed in 2015 by the Japanese Ministry of Health and Welfare using positron emission tomography and cardiac MRI findings as major criteria and substituting histological verification. We present a case of a 60-year-old woman with pulmonary sarcoidosis presenting with progressively worsening palpitations and recurrent syncope. Her initial evaluation at another hospital facility revealed normal cardiac testing. A detailed evaluation with echocardiography and cardiac MRI helped us arrive at the diagnosis of CS, which resulted in appropriate treatment and resolution of symptoms. We discuss CS in general, the clinical disease, diagnostic algorithms, latest guidelines and management


2020 ◽  
Vol 75 (11) ◽  
pp. 307
Author(s):  
Bharat Narasimhan ◽  
Dhrubajyoti Bandyopadhyay ◽  
Ashish Correa ◽  
Davendra Mehta

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
K Bhatia ◽  
R Ramirez ◽  
B Narasimhan ◽  
S Walsh ◽  
K Sud ◽  
...  

Abstract Background Sarcoidosis is a chronic inflammatory disorder of unclear etiology, characterized by the presence of non-caseating granulomas. Cardiac involvement occurs in upto 27 percent of patients, manifesting as atrioventricular blocks, ventricular arrhythmia or sudden cardiac death. Current guidelines cite insufficient evidence for the prognostic utility of positron emission tomography (PET) in patients with cardiac sarcoidosis. Thus, we performed a systematic review and meta-analysis of published studies to ascertain the prognostic significance of PET imaging in patients with suspected or diagnosed cardiac sarcoidosis. Purpose To review current literature and determine if PET has prognostic utility in patients with known or suspected cardiac sarcoidosis Methods We performed a comprehensive literature search of electronic databases (Embase, Medline and Web of Science) using MeSH terms and keywords for sarcoidosis and PET from inception through December 2019. Studies were eligible if they included patients with known and/or suspected cardiac sarcoidosis undergoing evaluation by PET with or without perfusion imaging and reported clinical events of interest. An abnormal PET study was defined as the presence of focal or focal-on-diffuse uptake of 18- fluorodeoxyglucose (18-FDG) by visual analysis. In studies with perfusion imaging, patients with only perfusion defects were excluded. The primary outcome of interest was a composite of major adverse cardiac events (MACE), including sustained ventricular tachycardia, sudden cardiac death. Secondary analysis studied association of MACE with focal right ventricular (RV) uptake in patients with an abnormal PET study. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects model. Heterogeneity of results among the studies was assessed using the Higgins I2 value. Results Out of a total of 1645 citations, 40 were selected for full-text review. Five studies were included in the final analysis with a total of 465 patients. mean follow-up was 2.3 years. Three of the five studies also reported frequency of abnormal RV uptake of 18-FDG. Patients with abnormal 18-FDG uptake on visual assessment had higher odds of MACE (OR 3.12, CI 1.9–5.01, p<0.00001), compared to known or suspected cardiac sarcoid patients with normal PET studies. Heterogeneity among studies was low (I2 = 0). In patients with an abnormal PET study, abnormal focal RV uptake of 18-FDG was associated with higher odds of MACE (OR 5.24, CI 1.1–25.1, p=0.04), with moderate heterogeneity among studies (I2=41). Conclusion In patients undergoing PET imaging for known or suspected cardiac sarcoidosis, abnormal metabolism on visual analysis is associated with increased risk of MACE. Furthermore, focal RV uptake further increases the risk of MACE in patients with abnormal PET imaging. Thus, PET imaging can serve as a tool to risk stratify patients with known or suspected cardiac sarcoidosis. Forrest Plots Funding Acknowledgement Type of funding source: None


2015 ◽  
Vol 31 (1) ◽  
pp. 103.e9-103.e11 ◽  
Author(s):  
Juan Quintanilla ◽  
Cesar Avila ◽  
Manuel Meraz ◽  
Carlos Jerjes-Sanchez ◽  
Erasmo de la Peña-Almaguer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document